[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367992-105":59,"doc-detail-367992-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","integrated-screening-for-small-molecules-interfering-with-pkm2-a-drug-repurposing-strategy-against-glioblastoma","Integrated screening for small molecules interfering with PKM2: a drug repurposing strategy against glioblastoma","","Glioblastoma (GBM), the most aggressive adult brain tumor, continues to pose major clinical challenges. Pyruvate kinase M2 (PKM2) modulates GBM metabolism and tumorigenesis by switching between tetrameric (metabolic) and dimeric (oncogenic) forms, thereby regulating the Warburg effect. The study evaluates a drug repurposing strategy to discover clinically approved drugs that stabilize PKM2 in its tetrameric form, aiming to disrupt GBM metabolic adaptability and oncogenic potential.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-screening-for-small-molecules-interfering-with-pkm2-a-drug-repurposing-strategy-against-glioblastoma/367992/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-screening-for-small-molecules-interfering-with-pkm2-a-drug-repurposing-strategy-against-glioblastoma/367992.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PKM2 play in glioblastoma progression?","Question",{"text":112,"@type":113},"PKM2 drives GBM metabolism and tumorigenesis by switching between tetrameric (metabolic) and dimeric (oncogenic) forms, thereby regulating the Warburg effect.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the integrated screening strategy conducted?",{"text":117,"@type":113},"The study used a multi-step workflow combining virtual screening, pharmacological data analysis, and in vitro cellular assays on GBM cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcomes of the drug repurposing screening?",{"text":121,"@type":113},"From thousands of clinically approved drugs, three candidates reduced GBM cell viability, lowered PKM2 nuclear localization, and impaired glycolytic activity, supporting attenuation of the Warburg effect.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is this PKM2-targeting approach considered applicable beyond glioblastoma?",{"text":125,"@type":113},"Metabolic reprogramming and the Warburg effect are common hallmarks across many cancers, suggesting potential for broader tumor applications.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},367992,1790617957,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Costantini etal. Journal of Translational Medicine (2025) 23:1388  \n[https://doi.org/10.1186/s12967-025-07444-9](https://doi.org/10.1186/s12967-025-07444-9)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nIntegrated screening for small molecules interfering with PKM2: a drug repurposing strategy against glioblastoma  \nSusan Costantini 1†, Isabella Romeo2†, Giulia Fanelli3, Maria Serena Roca 1, Gianmarco Gualtieri2, Palmina Bagnara 1, Andrea Polo 1,4, Elena Di Gennaro 1, Francesco Ortuso2, Stefano Alcaro2, Alfredo Budillon5, Gennaro Ciliberto6, Marco G. Paggi3* and Claudia Abbruzzese3*  \nAbstract  \nBackground Glioblastoma (GBM), the most aggressive adult brain tumor, remains a significant clinical challenge. Pyruvate kinase M2 (PKM2), by shifting between its tetrameric (metabolic) and dimeric (oncogenic) forms, drives GBM metabolism and tumorigenesis, regulating the Warburg effect. This study explores a drug repurposing strategy to identify clinically approved medications capable of stabilizing PKM2 in its tetrameric form, thus disrupting GBM metabolic adaptability and oncogenic potential.  \nMethods We employed a multi-step screening strategy that integrates virtual screening, pharmacological data analysis, and in vitro cellular assays performed on anchorage-dependent and-independent GBM cell lines. This methodological process highlights the potential of repurposable drugs to target a cancer-specific metabolic vulnerability, thereby accelerating the development of novel therapeutic strategies for GBM.  \nResults From thousands of clinically approved drugs, we selected, among those potentially able to cross the bloodbrain barrier, three candidates that significantly inhibited GBM cell viability, reduced PKM2 nuclear localization, and impaired glycolytic activity, suggesting their potential to attenuate the Warburg effect and tumor malignancy. Conclusions We established a detailed screening protocol for drug repurposing to treat GBM. This approach targets a critical vulnerability of GBM cells by disrupting their bioenergetic balance. Since metabolic reprogramming and the associated Warburg effect are hallmarks of many cancers, not just GBM, we believe this approach holds significant potential for use against a wider range of tumors.  \nKeywords Glioblastoma, PKM2, Drug screening, Drug repurposing  \n†Susan Costantini and Isabella Romeo contributed equally to this work.  \n*Correspondence:  \nMarco G. Paggi [marco.paggi@ifo.it](marco.paggi@ifo.it)[ ](marco.paggi@ifo.it)Claudia Abbruzzese [claudia.abbruzzese@ifo.it](claudia.abbruzzese@ifo.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nCostantini et al. Journal of Translational Medicine (2025) 23:1388 Page 2 of 13  \nGraphical Abstract  \nIntroduction  \nGlioblastoma (GBM) is the most common and aggressive brain tumor in adults, with a global incidence of 3.2 per 100,000 population [1","cbCaiaJmpgkNVb4K","https://ap.wps.com/l/cbCaiaJmpgkNVb4K","pdf",2341086,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Current clinical challenge in GBM\n## Drug repurposing rationale\n## Prior work on chlorpromazine\n## PKM2 biology and the Warburg effect","[{\"question\":\"What role does PKM2 play in glioblastoma progression?\",\"answer\":\"PKM2 drives GBM metabolism and tumorigenesis by switching between tetrameric (metabolic) and dimeric (oncogenic) forms, thereby regulating the Warburg effect.\"},{\"question\":\"How was the integrated screening strategy conducted?\",\"answer\":\"The study used a multi-step workflow combining virtual screening, pharmacological data analysis, and in vitro cellular assays on GBM cell lines.\"},{\"question\":\"What were the main outcomes of the drug repurposing screening?\",\"answer\":\"From thousands of clinically approved drugs, three candidates reduced GBM cell viability, lowered PKM2 nuclear localization, and impaired glycolytic activity, supporting attenuation of the Warburg effect.\"},{\"question\":\"Why is this PKM2-targeting approach considered applicable beyond glioblastoma?\",\"answer\":\"Metabolic reprogramming and the Warburg effect are common hallmarks across many cancers, suggesting potential for broader tumor applications.\"}]","Integrated screening for small molecules interfering with PKM2: a drug repurposing strategy against glioblastoma | PDF",1790174227,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53f776ab4b5b5fed27c612f3ec0213f7.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a521fc67b3b10c3f63ebdcd250e693c2.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09b62215e3d968461f37403311103c41.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6795f6977cc5aefa395f9d4d970701b.webp",980,1306]